Anas Fathallah

Form D signer

Anas Fathallah

President at Lapix Therapeutics

Form D signer

Capital raised by Lapix Therapeutics

$7.7M+$2.2M latest round

2 Form D filings · first filed Aug 2024 · Boston, MA

CURRENT ROLE: President
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 3
FOUNDED: —
30D INTEREST: 3 ↗

Career

1 company on file

Lapix TherapeuticsBiotech · Boston, MAsince Aug 2024

President

Signatory on Lapix Therapeutics's Form D filings · $7.7M raised across 2

Company filings

via EDGAR · Form D for Lapix Therapeutics2

DateCompanyFormAmountRole on filing

Jul 21, 2025Lapix TherapeuticsForm D+$2.2MPresident

Form DJul 21, 2025 · Lapix Therapeutics+$2.2Mas President

Aug 2, 2024Lapix TherapeuticsForm D/A+$5.5MPresident

Form D/AAug 2, 2024 · Lapix Therapeutics+$5.5Mas President

Overview

Last filing Jul 21, 2025

Anas Fathallah is on file as President at Lapix Therapeutics in Boston, MA. Lapix Therapeutics has 2 Form D filings on record, $7.7M raised in total. Anas Fathallah appears as a signatory on the company's filings.

Teammates

Lapix Therapeutics · 2

Anthony GibneyDirector Francisco LeonDirector

Products

Lapix Therapeutics · 1

LPX-TI641Immune restoration drug

LPX-TI641 is an oral small-molecule drug developed to target the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is designed to restore the body’s natural immune tolerance in patients with autoimmune diseases.